ES2167322T3 - Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion. - Google Patents

Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion.

Info

Publication number
ES2167322T3
ES2167322T3 ES93113602T ES93113602T ES2167322T3 ES 2167322 T3 ES2167322 T3 ES 2167322T3 ES 93113602 T ES93113602 T ES 93113602T ES 93113602 T ES93113602 T ES 93113602T ES 2167322 T3 ES2167322 T3 ES 2167322T3
Authority
ES
Spain
Prior art keywords
bone
osf
protein
cadherinic
procedure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93113602T
Other languages
English (en)
Inventor
Sunao Takeshita
Makoto Okazaki
Shinji Kawai
Atsushi Tsujimura
Egon Dr Amann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanofi Aventis UK Holdings Ltd
Original Assignee
Aventis Pharma Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pharma Ltd filed Critical Aventis Pharma Ltd
Application granted granted Critical
Publication of ES2167322T3 publication Critical patent/ES2167322T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

UNA PROTEINA REFERIDA A LOS HUESOS LLAMADA OSF-$ QUE SE OBTIENE A PARTIR DE TEJIDO OSEO DE UN MAMIFERO INCLUIDO RATONES Y HUMANOS, Y UN PROCESO PARA SU PRODUCCION. ESTA PROTEINA ES UNA NUEVA PROTEINA DE MAMIFERO QUE SE DA NATURALMENTE DE LA FAMILIA CADHERINA. LA OSF-4 ACTUA COMO UNA MOLECULA DE ADHESION O UN FACTOR DE CRECIMIENTO QUE TOMA PARTE EN EL PROCESO DE OSTEOGENESIS EN EL LUGAR DE LA INDUCCION DEL HUESO. OSF-4 PUEDE SER USADA COMO UN AGENTE PARA TRATAR ENFERMEDADES METABOLICAS DE LOS HUESOS, Y SU GRAN ESPECIFICIDAD DE ORGANO PARA HUESOS PERMITE SU USO COMO UN REAGENTE DE DIAGNOSTICO PARA ENFERMEDADES METABOLICAS DE LOS HUESOS.
ES93113602T 1992-08-28 1993-08-25 Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion. Expired - Lifetime ES2167322T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP23002892 1992-08-28

Publications (1)

Publication Number Publication Date
ES2167322T3 true ES2167322T3 (es) 2002-05-16

Family

ID=16901442

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93113602T Expired - Lifetime ES2167322T3 (es) 1992-08-28 1993-08-25 Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion.

Country Status (10)

Country Link
US (1) US5869638A (es)
EP (1) EP0585801B1 (es)
JP (1) JP3560252B2 (es)
AT (1) ATE208420T1 (es)
AU (1) AU663216B2 (es)
CA (1) CA2104997A1 (es)
DE (1) DE69331086T2 (es)
DK (1) DK0585801T3 (es)
ES (1) ES2167322T3 (es)
PT (1) PT585801E (es)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06121678A (ja) * 1992-08-28 1994-05-06 Hoechst Japan Ltd 骨関連サルファターゼ様タンパク質およびその製造法
EP0832195B1 (de) 1995-06-07 2005-11-09 co.don Aktiengesellschaft Verfahren zur osteoporosediagnose und zur testung potentieller osteoporose-therapeutika unter verwendung von standardisierten, primären osteoblastenzellkulturen aus osteoporotischen patienten
EP1023445B1 (de) 1997-10-15 2005-08-17 Pharis Biotec GmbH Cadherin derived growth factor und seine verwendung
US7481999B2 (en) 1998-05-05 2009-01-27 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin-mediated function
US6472367B1 (en) * 1998-05-05 2002-10-29 Adherex Technologies, Inc. Compounds and methods for modulating OB-cadherin mediated cell adhesion
WO2001090145A2 (en) * 2000-05-19 2001-11-29 Millennium Pharmaceuticals, Inc. 57805, a human cadherin family member and uses thereof
WO2007038683A2 (en) * 2005-09-28 2007-04-05 The Regents Of The University Of California Calcium binding peptides
KR101695056B1 (ko) * 2010-07-15 2017-01-10 애드헤론 쎄라퓨틱스, 인코포레이티드 카드헤린-11의 ec1 도메인을 표적으로 하는 인간화 항체 및 관련 조성물 및 방법

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT98109A (pt) * 1990-06-29 1992-07-31 Hoechst Japan Processo recombinante para a preparacao duma nova proteina
AU2240492A (en) * 1991-06-20 1993-01-25 United States Of America, As Represented By The Secretary, Department Of Health And Human Services, The Sequences characteristic of human gene transcription product
EP0604603A4 (en) * 1992-04-17 1996-09-25 Doheny Eye Inst ELEMENTS AND METHODS FOR THE PRODUCTION OF CADHERINES.
JP3472587B2 (ja) * 1992-08-28 2003-12-02 アベンティス ファーマ株式会社 骨関連カルボキシペプチダーゼ様タンパク質およびその製造法
DE4228839A1 (de) * 1992-08-29 1994-03-03 Behringwerke Ag Verfahren zum Nachweis und zur Bestimmung von Mediatoren

Also Published As

Publication number Publication date
EP0585801A3 (en) 1994-06-29
EP0585801A2 (en) 1994-03-09
DE69331086T2 (de) 2002-06-06
US5869638A (en) 1999-02-09
PT585801E (pt) 2002-04-29
JPH06122700A (ja) 1994-05-06
CA2104997A1 (en) 1994-03-01
EP0585801B1 (en) 2001-11-07
JP3560252B2 (ja) 2004-09-02
DE69331086D1 (de) 2001-12-13
ATE208420T1 (de) 2001-11-15
DK0585801T3 (da) 2002-03-11
AU4492293A (en) 1994-03-03
AU663216B2 (en) 1995-09-28

Similar Documents

Publication Publication Date Title
EA200300845A1 (ru) Модифицированные антитела и способы применения
EA200000298A1 (ru) Агонисты простагландинов и их применение для лечения заболеваний костей
ATE468137T1 (de) Inhibitoren von hmgb1 zur behandlung von gewebekrankheiten
ATE298800T1 (de) Verfahren und desoxyribonukleinsäure zur herstellung von gewebefaktor-protein
DE3856594D1 (de) Mittel zur behandlung der alzheimer-krankheit
BR9910570A (pt) Aparelho para o tratamento de distúrbios de tecido e/ou das juntas
DK0881908T3 (da) Anvendelse af fiberblastvækstfaktorer til stimulering af knoglevækst
NO174392C (no) Analogifremgangsmåte for fremstilling av acyldeoksyribonukleosidderivater
SE8704248D0 (sv) Medical use
FR2595235B1 (fr) Endoscope ou technoscope video pour examen de cavites du corps humain
ES2147556T3 (es) Proteina relativa al hueso, del tipo carboxipeptidasa y procedimiento para su produccion.
ATE67094T1 (de) Knochenzement.
ES2167322T3 (es) Proteina de tipo cadherinico relacionada con los huesos y procedimiento para su preparacion.
DE69010294D1 (de) Verwendung von Antiprogestomimetika zur Stimulierung des Eisprungs.
ATE124681T1 (de) Arzneimittelzusammensetzungen zur behandlung von psoriasis.
PT83309B (de) Neue pyrrolo-benzimidazole pyrrolo-benzoxazole und pyrrolo-benzthiazole verfahren zu ihrer herstellung und diese verbindungen enthaltende arneimittel
ES545155A0 (es) Procedimiento para la obtencion de (pirrol-1-il)-fenil-dihi-dropiridazinona
NO910033D0 (no) Fremgangsmaate for fremstilling av terapeutisk aktive 2-hydroksy-3-fenoksypropylaminoforbindelser.
DK0590309T3 (da) Knoglevævsbeslægtet protein, fremgangsmåde til dets fremstilling samt lægemiddel med indhold deraf
ATE220915T1 (de) Einen basischen fibroblastwachstumsfaktor enthaltende mittel zur behandlung von knochenkrankheiten
GB8812533D0 (en) Instrument for surgical treatment of pieces of tissue
ES2044853T3 (es) Derivados de 1,4-di-hidro-piridina, procedimiento para su fabricacion y medicamentos que contienen estos compuestos.
ATE67931T1 (de) Butylhydroxyanisole zur behandlung von retrovirus-krankheiten.
SU1438725A1 (ru) Способ лечени ложных суставов
SE8204625D0 (sv) Method for stimulating the synthesis of the melanotic pigment of the skin